ProstaScint

ProstaScint®

Capromab pendetide, see there.
References in periodicals archive ?
In the US, the company currently markets Natesto nasal formulation of testosterone for men with hypogonadism, and ProstaScint (capromab pendetide) imaging agent specific to prostate specific membrane antigen for prostate cancer detection and staging.
Healthcare company Aytu BioScience (RSWN) revealed on Tuesday the launch of an agreement to acquire the rights to ProstaScint from Jazz Pharmaceuticals (NasdaqGS:JAZZ).
(OTC: RSWN) has entered into an agreement with Jazz Pharmaceuticals (NASDAQ: JAZZ) to acquire Jazz Pharmaceuticals' rights to ProstaScint, an imaging agent used to detect the extent and spread of prostate cancer that is marketed in the US, the company said.
It is believed that successful imaging with [sup.111]In- labeled 7E11 monoclonal antibody (ProstaScint) results from mAb binding to antigen exposed in dead or dying cells within some tumor sites (2).
Few clinicians still use imaging with the first-generation [sup.111]indium-labeled monoclonal antibody Prostascint to PSMA to differentiate soft tissue metastases from bone metastases, he said.
Few clinicians still use imaging with the first-generation [.sup.111]indium-labeled monoclonal antibody Prostascint to PSMA to differentiate soft tissue metastases from bone metastases, he said.
Bard, alleging that use of their ProstaScint product infringed United States Patent 4,460,559, which claims a method for detecting and localizing tumors.
Called ProstaScint, this MAB-radioisotope conjugate seeks and binds to PSMA molecules located on the surfaces of primary and metastatic prostate cancers.
ProstaScint Scan -- This test uses an isotope of Iridium 111 to detect the growth of prosate cancer cells outside the prostate, locally to the prostate, and throughout the body.
Currently marketed products include ProstaScint (a monoclonal antibody- based imaging agent used to image the extent and spread of prostate cancer); BrachySeed I-125 and Pd-103 (two uniquely designed, next- generation radioactive seed implants for the treatment of localized prostate cancer); and Quadramet (a skeletal targeting therapeutic radiopharmaceutical marketed for the relief of bone pain in prostate and other types of cancer).
FDA-approved products include ProstaScint (a monoclonal antibody-based imaging agent used to image the extent and spread of prostate cancer); BrachySeed(TM) I-125 and Pd-103 (uniquely designed, next-generation radioactive seed implants for the treatment of localized prostate cancer); and Quadramet (a therapeutic agent marketed for the relief of bone pain in prostate and other types of cancer).